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Desmoplastic melanocytic nevi can be difficult to distinguish from
desmoplastic melanoma. The presence of lymphocytic aggregates in
association with a sclerosing melanocytic proliferation is commonly
regarded as a feature in support of a diagnosis of desmoplastic
melanoma. However, the finding is not specific for melanoma. Herein
we report six cases of sclerosing melanocytic nevi with associated
lymphocytic aggregates. They occurred in five women and one man,
ranging in age from 11 to 61 years. Three lesions were sclerosing Spitz
nevi; one was an amelanotic sclerosing blue nevus, one an acquired
intradermal sclerosing nevus, and one was a congenital compound
melanocytic nevus with sclerosis of its dermal component. The lesions
were interpreted as benign, i.e. melanocytic nevi, because of their
histopathologic attributes (symmetric silhouette, benign cytologic
features) and results from immunohistochemical studies (all lesions
strongly expressed Melan-A and p16) and fluorescence in situ
hybridization (FISH). Three lesions tested by FISH lacked copy
number changes of 11p, 6q or 6p. None of the lesions recurred. The
cases highlight that contextual information is essential for the diagnosis
of desmoplastic melanoma and sclerosing nevus. The presence of
lymphocytic aggregates per se does not prove that a sclerosing
melanocytic proliferation is malignant.
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Desmoplastic melanoma is a rare variant of
cutaneous melanoma characterized by a prominent
collagenous stroma.1,2 It tends to affect chronically
sun-damaged skin of elderly Caucasians, but
can also develop in skin of younger individuals
without significant solar elastosis.1– 7 Desmoplastic
melanoma is clinically characterized by a higher
tendency for local recurrence and less frequent
regional lymph node involvement than conventional
melanoma.5– 7
Desmoplastic melanoma can be difficult to
diagnose clinically and histopathologically.1,2,8,9
Failure to recognize desmoplastic melanoma
amounts to a significant proportion of medical
malpractice claims related to melanoma.10 Under
the microscope, desmoplastic melanoma can be
confused with non-melanocytic spindle cell tumors,
such as spindle cell squamous cell carcinoma or
a sarcoma.1,8,9 It may simulate the appearance of
a scar. A particularly diagnostic challenge is its
distinction from a sclerosing melanocytic nevus,
especially on a partial shave biopsy of a clinically
indistinct lesion.1,9,11 – 15
A number of pathologic parameters are useful
for the recognition of desmoplastic melanoma
and its distinction from a sclerosing melanocytic
nevus.1,11 – 15 One feature that is commonly
mentioned as helpful for the diagnosis of desmoplastic
melanoma is the presence of lymphocytic aggregates.
However, such lymphocytic aggregates are not
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unique for melanoma. They can be seen in other
fibrosing lesions, including sclerosing melanocytic
nevi. Herein we report six cases of sclerosing
melanocytic nevi with lymphocytic aggregates to
document the occurrence of this association. Our
findings confirm limits in the specificity of the
diagnostic value of lymphocytic aggregates.
Materials and methods
Case selection
The cases were collected from the clinical material
of two authors with an interest in this topic. No
diagnostically ambiguous cases were included.
Immunohistochemical studies
Five micron thick sections from formalin-fixed and
paraffin-embedded tissue blocks were taken and
analyzed immunohistochemically using standard
avidin–biotin procedure. An automated IHC system
(Ventana BenchMark XT, Ventana Medical Sys-
tems, Inc., Tucson, AZ, USA) using an alkaline phos-
phatase method and a red chromogen was used. The
antibodies tested included S100 protein (Cell Mar-
que, Hot Springs, AR, USA), A103 (Dako, Glostrup,
Denmark), p16 (Dako), CD3 (Dako), CD79a (Dako),
CD4 (Ventana Medical Systems, Inc.) and CD8
(Ventana Medical Systems, Inc.). They were used
according to the manufacturer’s instructions.
Fluorescence in situ hybridization
Fluorescence in situ hybridization (FISH) test-
ing was performed using four probes target-
ing Ras Responsive Element-Binding Protein-1
(Vysis®LSI® RREB1-Spectrum Red), myeloblas-
tosis (Vysis®LSI® MYB-S Gold), cyclin D1 or
chromosome 11q (Vysis®LSI® CCND1-Spectrum
Green™), and centromeric enumeration probe
control for chromosome 6 (Vysis®LSI® CEP6-
Spectrum Aqua) from Abbott Molecular, Inc. (Des




The six lesions reported herein affected five female
and one male patient. Their ages ranged from 11 to
61 years (mean = 31 years, median = 33 years). The
sites affected included the ear (two lesions), eyelid,
chest, back and arm. The biopsies were submitted
as rule out nevus vs. fibroma. There has been no
recurrence within the available follow-up period
(range 3 months to 10 years, mean = 2.5 years,
median = 1.7 years).
Fig. 1. Wedge-shaped symmetric silhouette of an intradermal pauci-
cellular sclerosing nevus with lymphocytic aggregates in the reticular
dermis.
Fig. 2. Compound melanocytic nevus with sclerosis. Nests of
melanocytes are present at the dermoepidermal junction and in
the superficial dermis. Solitary units of melanocytes predominate
within sclerotic dermis. Lymphocytic aggregates are present at the
base.
Histopatholgic features
Three lesions were compound melanocytic nevi.
Three were intradermal. Their silhouettes were
wedge-shaped and symmetric (Fig. 1). Due to the
associated sclerosis they had a ‘pink’ appearance
at scanning magnification. In the cases of the
compound nevi, the junctional component showed a
predominant nested growth pattern and was periph-
erally confined to the area overlying the dermal
melanocytes (Fig. 2). All lesions showed evidence of
maturation with dispersion of cells into solitary units
at the base of the dermal nevus component. None
of them contained an intradermal melanocyte in
mitosis.
Three of the sclerosing nevi show spitzoid cytology
(Fig. 3). The remaining three lesions included
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Fig. 3. Sclerosing Spitz nevus with epithelioid melanocytes adjacent
to a lymphocytic aggregate.
a sclerosing pauci-melanotic blue nevus, irritated
intradermal sclerosing melanocytic nevus and one
congenital melanocytic nevus with sclerosis of its
dermal component.
The lymphocytic aggregates were typically present
in the mid or deep reticular dermis (Figs. 1–3). The
number of lymphocytic aggregates per lesion ranged
from 1 to 7 (mean = 3, median = 3). They were




Fig. 4. Sclerosing Spitz nevus with lymphocytic aggregates. A) Hematoxylin and eosin-stained section. B–D) Immunohistochemical staining
for S100 protein (B), melan-A (C) and p16 (D).
Immunohistochemical findings
The intradermal spindle cells of all lesions
were strongly and diffusely immunoreactive for
S100 protein, Melan-A and p16. A typical
immunohistochemical profile is illustrated in Fig. 4.
In all lesions, the Mib-1 labeling index of intradermal
melanocytes was <2%.
In three cases there was sufficient material to
immunophenotype the lymphocytic aggregates. All
aggregates were composed of a mixture of T and
B-cells (Fig. 5). The population of T-cells included
both CD4 and CD8-positive cells.
Cytogenetic findings
Three of the six cases were examined cytogenetically
by FISH analysis, using four probes to loci on 6p,
6q, 6 cent and 11q and previously published criteria.
None of the cases show chromosomal copy number
gains or losses diagnostic for melanoma.
Discussion
Desmoplastic melanoma is a distinct variant of
melanoma characterized by prominent stromal
fibrosis.1,2 Stromal desmoplasia, however, may also
be associated with a melanocytic nevus, including
conventional (‘common acquired’), Spitz or blue
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Fig. 5. Immunophenotype of the lymphocytic aggregates. A and B) Sclerosing melanocytic nevus with lymphocytic aggregates (H&E).
Immunohistochemical staining for CD3 (C), CD79a (D), CD4 (E) and CD8 (F).
nevus.11 – 15 Distinguishing desmoplastic melanoma
from a desmoplastic or sclerosing melanocytic nevus
can be challenging, especially on a small partial
biopsy.1,9,11 – 15 Clinical features can be helpful, but
are of limited value because of significant overlap.
Histopathologically, the distinction between
desmoplastic melanoma and a sclerosing melanocytic
nevus usually can be made with confidence, if
one is given an adequate excisional biopsy of
the lesion that permits evaluation of parameters
relevant for the diagnosis.1,11 – 15 If the desmoplastic
dermal melanocytic proliferation is accompanied by
intraepidermal (in situ) melanoma, the diagnosis is
straightforward. However, in approximately one
third of desmoplastic melanomas, there is no
in situ melanoma detectable within the epidermis.1– 3
In these cases, one needs to rely entirely on
the features of the intradermal melanocytes.
Desmoplastic melanoma typically displays an
infiltrative asymmetric silhouette and often extends
into the subcutis. Sclerosing nevi tend to be
symmetric, more broad than deep and confined
to the dermis. Desmoplastic melanoma is usually
amelanotic. Sclerosing nevi are more likely to contain
pigment, at least focally. Desmoplastic melanoma
characteristically contains hyperchromatic elongated
fusiform melanocytes. Sclerosing nevi, especially
sclerosing Spitz’s nevi, are more likely to contain
epithelioid melanocytes with open chromatin and
distinct nucleoli.
Ancillary studies have been forwarded for use
in cases in which the distinction of desmoplastic
melanoma from a melanocytic nevus is difficult.
Commonly used immunohistochemical markers in
this setting include Melan-A/Mart-1,18 Ki-67,18 and
p16.19 Desmoplastic melanomas tend to have a
higher Ki-67 labeling index than melanocytic nevi
and are often negative for Melan-A/Mart-1 and p16,
while sclerosing nevi usually lack staining for Ki-67
and tend to be strongly immunoreactive for Melan-
A/Mart-1 and p16. However, exceptions exist. Cyto-
genetic methods have also been explored and it has
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been documented that a 4 probe FISH assay targeting
RREB1, MYB, Cep6 and CCND1,16,17 can help in
this setting albeit with limited sensitivity. While a pos-
itive test would support the diagnosis of melanoma,
a negative result does not exclude melanoma. A
melanoma may have copy number changes involving
chromosomes not tested by this assay.
Apart from properties of the tumor cells
(histopathologic appearance, immunophenotype,
cytogenetic findings), the diagnostic evaluation of
a sclerosing melanocytic proliferation also takes into
account stromal findings (e.g. presence or absence
of solar elastosis) and inflammatory changes. With
regard to the latter, lymphocytic aggregates are
commonly mentioned as a helpful diagnostic feature
for the diagnosis of desmoplastic melanoma.1,2,8,9
However, little is known about the sensitivity and
specificity of this feature for the distinction of
desmoplastic melanoma from sclerosing melanocytic
nevi. In a review of 20 randomly selected cases
of desmoplastic melanomas, we found lymphocytic
aggregates in 17 cases (85%; KJB; unpublished
observations). Among 20 cases of randomly selected
sclerosing nevi only three lesions (15%) were
associated with lymphocytic aggregates (KJB, RP;
unpublished observations). While a more systematic
assessment of this issue on a larger number of
cases is desirable, it can be stated already that
lymphocytic aggregates, albeit frequently present are
not a constant feature of desmoplastic melanomas.
Furthermore even if they are present, they may
only be noted in a full thickness excision in
the deeper portion of the tumor. It can also
said that while lymphocytic aggregates seem to
be present only in a minority of sclerosing nevi,
they do occur, as documented herein. Thus, the
feature per se is insufficient evidence for malignancy.
The association of lymphocytic aggregates with a
benign sclerosing melanocytic proliferations should
not come as a surprise, because lymphocytic
aggregates have been known to occur in association
with an inflammatory fibrosing process, such as
a scar or morphea. The findings in the current
report do not diminish the value of lymphocytic
aggregates prompting concerns about desmoplastic
melanoma. However, our observation should caution
pathologists to find additional evidence in support of
or against melanoma before rendering a diagnosis.
The presence of lymphocytic aggregates per se is
simply not specific enough for melanoma.
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